Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Assets Average (2016 - 2025)

Historic Assets Average for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $579.7 million.

  • Viridian Therapeutics, Inc.\DE's Assets Average fell 1459.24% to $579.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $579.7 million, marking a year-over-year decrease of 1459.24%. This contributed to the annual value of $616.4 million for FY2024, which is 3320.44% up from last year.
  • Viridian Therapeutics, Inc.\DE's Assets Average amounted to $579.7 million in Q3 2025, which was down 1459.24% from $621.7 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Assets Average peaked at $757.2 million during Q4 2024, and registered a low of $120.5 million during Q2 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Assets Average value was $409.6 million (recorded in 2023), while the average stood at $409.5 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Assets Average surged by 41178.71% in 2021, and later tumbled by 1459.24% in 2025.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Assets Average stood at $212.5 million in 2021, then skyrocketed by 106.08% to $437.8 million in 2022, then fell by 6.45% to $409.6 million in 2023, then skyrocketed by 84.86% to $757.2 million in 2024, then dropped by 23.43% to $579.7 million in 2025.
  • Its last three reported values are $579.7 million in Q3 2025, $621.7 million for Q2 2025, and $701.7 million during Q1 2025.